IP Library Granted Patent US 12,447,332
Granted Patent B2
US 12,447,332 · App. 18/173,893 · Granted Oct 21, 2025

United states auricular nerve field stimulation device and methods for using the same

Inventors: Christopher R. Brown (Greensburg, IN); Gary M. Peterson (Versailles, IN)
Assignee: NEURAXIS, INC.
A61N1/0529A61N1/0551A61N1/36071A61K31/485
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,447,332
App. No.
18/173,893
Granted
Oct 21, 2025
Kind
B2
Abstract

An auricular nerve field stimulation device may include a first plurality of electrodes arranged to contact a ventral aspect of an auricle, a second plurality of electrodes arranged to contact a dorsal aspect of the auricle, and electrical circuitry coupled to the electrodes and configured to selectively apply electrical stimulation signals to the electrodes to cause a first set of trans-auricular currents to flow through the auricle between the first plurality of electrodes and respective ones of the second plurality of electrodes paired therewith according to a first pairing, and to cause a second set of trans-auricular currents to flow through the auricle between the first plurality of electrodes and respective ones of the second plurality of electrodes paired therewith according to a second pairing different from the first pairing, the first and second sets of trans-auricular currents to stimulate at least one auricular nerve field within the auricle. Methods of utilizing nerve field stimulation device.

Claims (52)

1. A method of treating the symptoms of abdominal pain or nausea comprising:

placing an electrical stimulation device in contact with an ear of a patient, the device comprising

i) at least one therapy electrode electrically coupled to the electrical stimulation device and configured for percutaneous insertion into an auricle of the ear of the patient near at least one neurovascular bundle,

ii) a processor, and

iii) a memory having software stored therein which, when executed by the processor, causes the processor to

a) control the electrical stimulation device to generate and deliver to the percutaneously inserted at least one therapy electrode electrical stimulation signals at a selected frequency with one of a positive and a negative pulse relative to a reference to stimulate at least one auricular peripheral nerve field within the auricle,

b) continually repeat (a) for a first duration,

c) following expiration of the first duration, control the electrical stimulation device to generate no electrical stimulation signals for a second duration, and

d) repeat (a) through (c) with the electrical stimulation signals having a modulated frequency; and

reducing the symptoms of abdominal pain or nausea by stimulating the at least one neurovascular bundle with the electrical stimulation device,

wherein the patient ranges in age from about 11 to about 19 years of age.

2. The method of claim 1 , wherein the abdominal pain is a functional abdominal pain disorder.

3. The method of claim 2 , wherein the functional abdominal pain disorder is irritable bowel syndrome.

4. The method of claim 1 , wherein the nausea is cyclic vomiting syndrome.

5. The method of claim 1 , wherein the at least one therapy electrode includes at least one needle for percutaneous insertion into the auricle.

6. The method of claim 1 , wherein the electrical stimulation device further comprises a plurality of therapy electrodes each electrically coupled to the electrical stimulation device and each including at least one needle for percutaneous insertion into the auricle, at least one of the plurality of therapy electrodes including a plurality of needles for percutaneous insertion into the auricle.

7. The method of claim 1 , wherein the stimulating the at least one neurovascular bundle alters the response characteristics of the amygdala neurons and lumbar spinal neurons.

8. The method of claim 1 , wherein the electrical stimulation device further comprises a plurality of electrode assemblies each having a first electrically conductive electrode carried by a first housing and configured to be percutaneously inserted into the auricle of the ear and a second electrically conductive electrode carried by a second housing and configured to non-percutaneously contact the auricle adjacent to the first electrically conductive electrode, wherein the first and second housings are attached to one another or are together of unitary construction, and wherein the first and second electrically conductive electrodes are electrically isolated from one another by the first and second housings, and

electrical circuitry coupled to the plurality of electrode assemblies and configured to selectively apply a first set of electrical stimulation signals only to the first electrically conductive electrodes to stimulate at least one auricular nerve field within the auricle, and to selectively apply a second set of electrical stimulation signals only to the second electrically conductive electrodes to further stimulate the at least one auricular nerve field.

9. The method of claim 6 , wherein the at least one needle is implanted within 2 mm of the at least one neurovascular bundle.

10. The method of claim 2 , wherein the functional abdominal pain disorder is functional dyspepsia.

11. A method of treating the symptoms of abdominal pain or nausea comprising:

placing an electrical stimulation device in contact with an ear of a patient, the device comprising

i) at least one therapy electrode electrically coupled to the electrical stimulation device and configured for percutaneous insertion into an auricle of the ear of the patient near at least one neurovascular bundle,

ii) a processor, and

iii) a memory having software stored therein which, when executed by the processor, causes the processor to

a) control the electrical stimulation device to generate and deliver to the percutaneously inserted at least one therapy electrode electrical stimulation signals at a selected frequency with one of a positive and a negative pulse relative to a reference to stimulate at least one auricular peripheral nerve field within the auricle,

b) continually repeat (a) for a first duration,

c) following expiration of the first duration, control the electrical stimulation device to generate no electrical stimulation signals for a second duration, and

d) repeat (a) through (c) with the electrical stimulation signals having a modulated frequency; and

reducing the symptoms of abdominal pain or nausea by stimulating the at least one neurovascular bundle with the electrical stimulation device,

wherein the stimulating the at least one neurovascular bundle alters the response characteristics of the amygdala neurons and lumbar spinal neurons.

12. The method of claim 11 , wherein the abdominal pain is a functional abdominal pain disorder.

13. The method of claim 12 , wherein the functional abdominal pain disorder is irritable bowel syndrome.

14. The method of claim 12 , wherein the functional abdominal pain disorder is functional dyspepsia.

15. The method of claim 11 , wherein the nausea is cyclic vomiting syndrome.

16. A method of treating the symptoms of abdominal pain or nausea comprising:

placing an electrical stimulation device in contact with an ear of a patient, the device comprising

i) at least one therapy electrode electrically coupled to the electrical stimulation device and configured for percutaneous insertion into an auricle of the ear of the patient near at least one neurovascular bundle,

ii) a processor,

iii) a memory having software stored therein which, when executed by the processor, causes the processor to

a) control the electrical stimulation device to generate and deliver to the percutaneously inserted at least one therapy electrode electrical stimulation signals at a selected frequency with one of a positive and a negative pulse relative to a reference to stimulate at least one auricular peripheral nerve field within the auricle,

b) continually repeat (a) for a first duration,

c) following expiration of the first duration, control the electrical stimulation device to generate no electrical stimulation signals for a second duration, and

d) repeat (a) through (c) with the electrical stimulation signals having a modulated frequency;

iv) a plurality of electrode assemblies each having a first electrically conductive electrode carried by a first housing and configured to be percutaneously inserted into the auricle of the ear and a second electrically conductive electrode carried by a second housing and configured to non-percutaneously contact the auricle adjacent to the first electrically conductive electrode, wherein the first and second housings are attached to one another or are together of unitary construction, and wherein the first and second electrically conductive electrodes are electrically isolated from one another by the first and second housings, and

v) electrical circuitry coupled to the plurality of electrode assemblies and configured to selectively apply a first set of electrical stimulation signals only to the first electrically conductive electrodes to stimulate at least one auricular nerve field within the auricle, and to selectively apply a second set of electrical stimulation signals only to the second electrically conductive electrodes to further stimulate the at least one auricular nerve field, and

reducing the symptoms of abdominal pain or nausea by stimulating the at least one neurovascular bundle with the electrical stimulation device.

17. The method of claim 16 , wherein the abdominal pain is a functional abdominal pain disorder.

18. The method of claim 17 , wherein the functional abdominal pain disorder is irritable bowel syndrome.

19. The method of claim 17 , wherein the functional abdominal pain disorder is functional dyspepsia.

20. The method of claim 16 , wherein the nausea is cyclic vomiting syndrome.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2023
From: BROWN, CHRISTOPHER R.; PETERSON, GARY M.
To: NEURAXIS, INC.
Reel/Frame 064886/0856 →
Continuity (19)
Continuation In Part 17725761 · Apr 21, 2022
Continuation 16534159 · Aug 7, 2019
Continuation 15488416 · Apr 14, 2017
Continuation In Part 18154375 · Jan 13, 2023
Continuation 17363620 · Jun 30, 2021
Continuation 16408004 · May 9, 2019
Continuation 16014169 · Jun 21, 2018
Continuation 15811278 · Nov 13, 2017
Continuation 15595185 · May 15, 2017
Continuation 14277158 · May 14, 2014
Continuation In Part 17715121 · Apr 7, 2022
Division 17040766
Provisional Application 62324598 · Apr 19, 2016
Provisional Application 62323369 · Apr 15, 2016
Provisional Application 61894270 · Oct 22, 2013
Provisional Application 62662995 · Apr 26, 2018
Provisional Application 63314028 · Feb 25, 2022
Provisional Application 63315371 · Mar 1, 2022
Related Publication 20230241375A1 · Aug 3, 2023
References Cited (83)
US 4646744A · Capel · 1987 [cited by applicant]
US 4865048A · Eckerson · 1989 [cited by applicant]
US 5084007A · Malin · 1992 [cited by applicant]
US 5094242A · Gleason et al. · 1992 [cited by applicant]
US 5458625A · Kendall · 1995 [cited by applicant]
US 6212433B1 · Behl · 2001 [cited by applicant]
US 6296652B1 · Qingman · 2001 [cited by applicant]
US 7092849B2 · Lafitte et al. · 2006 [cited by applicant]
US 7103417B1 · Segel et al. · 2006 [cited by applicant]
US 8428719B2 · Napadow · 2013 [cited by applicant]
US 8761872B2 · Hinrichsen et al. · 2014 [cited by applicant]
US 8942814B2 · Szeles · 2015 [cited by applicant]
US 9662269B2 · Brown et al. · 2017 [cited by applicant]
US 9782584B2 · Cartledge et al. · 2017 [cited by applicant]
US 9839577B2 · Brown · 2017 [cited by applicant]
US 9901734B2 · Bennett · 2018 [cited by applicant]
US 10010479B2 · Brown · 2018 [cited by applicant]
US 10052257B2 · Nageshwar · 2018 [cited by applicant]
US 10058478B2 · Schnetz et al. · 2018 [cited by applicant]
US 10086199B2 · Brown · 2018 [cited by applicant]
US 10130275B2 · Nageshwar · 2018 [cited by applicant]
US 10413719B2 · Brown et al. · 2019 [cited by applicant]
US 10695568B1 · Covalin · 2020 [cited by applicant]
US 10806928B2 · Sharma et al. · 2020 [cited by applicant]
US 20030050470A1 · An et al. · 2003 [cited by applicant]
US 20030149451A1 · Chomenky et al. · 2003 [cited by applicant]
US 20030167025A1 · Imran · 2003 [cited by examiner]
US 20040044390A1 · Szeles · 2004 [cited by applicant]
US 20060122675A1 · Libbus et al. · 2006 [cited by applicant]
US 20080051852A1 · Dietrich et al. · 2008 [cited by applicant]
US 20080146549A1 · Coleman · 2008 [cited by applicant]
US 20080249439A1 · Tracey et al. · 2008 [cited by applicant]
US 20100004715A1 · Fahey · 2010 [cited by applicant]
US 20100113965A1 · Kanevsky et al. · 2010 [cited by applicant]
US 20100168822A1 · Szeles · 2010 [cited by applicant]
US 20100262205A1 · De Ridder · 2010 [cited by applicant]
US 20110160811A1 · Walker · 2011 [cited by applicant]
US 20110190569A1 · Simon et al. · 2011 [cited by applicant]
US 20120035680A1 · Napadow · 2012 [cited by applicant]
US 20120226333A1 · Szeles · 2012 [cited by applicant]
US 20130150923A1 · Schnetz et al. · 2013 [cited by applicant]
US 20140081368A1 · Szeles · 2014 [cited by applicant]
US 20140370476A1 · Nageshwar · 2014 [cited by applicant]
US 20140371608A1 · Nageshwar · 2014 [cited by applicant]
US 20140371621A1 · Nageshwar · 2014 [cited by applicant]
US 20150112405A1 · Brown et al. · 2015 [cited by applicant]
US 20150265830A1 · Simon et al. · 2015 [cited by applicant]
US 20150360030A1 · Cartledge et al. · 2015 [cited by applicant]
US 20160113526A1 · Nageshwar et al. · 2016 [cited by applicant]
US 20170087364A1 · Cartledge et al. · 2017 [cited by applicant]
US 20170143247A1 · Nageshwar · 2017 [cited by applicant]
US 20170197081A1 · Charlesworth et al. · 2017 [cited by applicant]
US 20170246081A1 · Brown · 2017 [cited by examiner]
US 20180064603A1 · Brown et al. · 2018 [cited by applicant]
US 20180200522A1 · Taca, Jr. · 2018 [cited by applicant]
US 20180296435A1 · Brown et al. · 2018 [cited by applicant]
US 20190262229A1 · Brown et al. · 2019 [cited by applicant]
US 20220072311A1 · Taca, Jr. · 2022 [cited by applicant]
AT 395106B · 1992 [cited by applicant]
EP 2474339A1 · 2012 [cited by applicant]
WO 2005001706A1 · 2005 [cited by applicant]
WO 2011030210A1 · 2011 [cited by applicant]
WO 2014200488A1 · 2014 [cited by applicant]
WO 2014200489A2 · 2014 [cited by applicant]
WO 2014200492A1 · 2014 [cited by applicant]
WO 2014207512A1 · 2014 [cited by applicant]
WO 2017044967A1 · 2017 [cited by applicant]
Office action for copending Korean Patent Application No. 10-2020-7034010, dated Jan. 22, 2024. Translation appended. [cited by applicant]
PCT International Search Report and Written Opinion completed by the ISA/US on Jan. 2, 2020 and issued in connection with PCT/US2019/029172. [cited by applicant]
Non-Final Office Action dated Mar. 19, 2018 filed in U.S. Pat. No. 10,010,479 issued Jul. 3, 2018. [cited by applicant]
Response and Terminal Disclaimer filed Apr. 10, 2018 to Non-Final Action dated Mar. 19, 2018 in U.S. Pat. No. 10,010,479 issued Jul. 3, 2018. [cited by applicant]
Non-Final Office Action dated Aug. 2, 2017 filed in U.S. Pat. No. 9,839,577 issued Dec. 12, 2017. [cited by applicant]
Response and Terminal Disclaimer filed Sep. 7, 2017 to Non-Final Office Action dated Aug. 2, 2017 in U.S. Pat. No. 9,839,577 issued Dec. 12, 2017. [cited by applicant]
Non-Final Office Action Dated Jul. 15, 2015 filed in U.S. Pat. No. 9,662,269 issued May 30, 2017. [cited by applicant]
Response filed Nov. 16, 2015 to Non-Final Office Action dated Jul. 15, 2015 in U.S. Pat. No. 9,662,269 issued May 30, 2017. [cited by applicant]
Final Office Action dated Feb. 25, 2016 filed in U.S. Pat. No. 9,662,269 issued May 30, 2017. [cited by applicant]
Response and Request for Continued Examination filed on Jun. 27, 2016 to Final Office Action dated Feb. 25, 2016 in U.S. Pat. No. 9,662,269 issued May 30, 2017. [cited by applicant]
Non-Final Office Action dated Jul. 28, 2016 filed in U.S. Pat. No. 9,662,269 issued May 30, 2017. [cited by applicant]
Response filed Aug. 25, 2016 to Non-Final Office Action dated Jul. 28, 2016 filed in U.S. Pat. No. 9,662,269 issued May 30, 2017. [cited by applicant]
Extended European Search Report in Application No. 19850021.7-1122 dated Dec. 17, 2021. [cited by applicant]
First Office Action issued in co-pending Japanese Application No. 2021-50996, dated Dec. 22, 2022. [cited by applicant]
Miranda, Adrian, and Arturo Taca. “Neuromodulation with percutaneous electrical nerve field stimulation is associated with reduction in signs and symptoms of opioid withdrawal: a multisite, retrospective assessment.” Th… [cited by applicant]
Roberts, Arthur and Christopher R. Brown. “Percutaneous Peri-Auricular Peripheral Nerve Field Stimulation: A Novel, Non-Opioid Therapy for Diabetic Neuropathy.” The Pain Practitioner, vol. 25, 3 (2015): 41-47. [cited by applicant]